Effect of cerivastatin on peripheral capillary permeability to albumin and peripheral nerve function in diabetic rats.
OBJECTIVE
To examine the effect of cerivastatin on capillary permeability to albumin and peripheral nerve function in diabetic rats.


METHODS
Diabetes was induced in male Wistar rats by i.p. injection of streptozotocin (STZ) at the age of 5 days. Forty diabetic rats were randomized in two groups: one treated by cerivastatin (diabetic treated group, DT) and the other untreated (diabetic untreated group, DU). The data were compared to a group of normal rats.


METHODS
The peripheral capillary filtration of albumin (CFA) was studied on a limb by a non-invasive isotopic method, and nerve electrophysiological measurements were performed. Rats were followed-up until 6 months. In group DU albumin retention (AR) increased by 3 months and lymphatic uptake of interstitial albumin was impaired at 6 months. None of these disorders was observed in group DT. Motor and sensory nerve conduction velocities (MNCV and SNCV) were significantly slower at 6 months in group DU but not in group DT as compared to control rats. The duration of the sensory nerve action potential (SNAP) was significantly longer in group DU than in control rats at 6 months whereas it did not differ in group DT and in control animals.


CONCLUSIONS
This study shows that cerivastatin may prevent the peripheral increase in CFA and lymphatic dysfunction induced by diabetes. These beneficial effects on microcirculation may be involved in the prevention of nerve function deterioration. The underlying mechanisms are likely to be independent of a lipid-lowering effect, but their clarification needs further investigations.
Cohen-Boulakia
F E
FE
Laboratory of Nutrition, Metabolic Diseases and Cardiovascular Prevention, Paris Nord University, hôpital Jean-Verdier, APHP, CRNH-IdF, avenue du 14-juillet, 93000 Bobigny, France.
Tarhzaoui
K
K
Valensi
P E
PE
Lestrade
R A
RA
Albertini
J P
JP
Behar
A
A
D000375:Aging; D000818:Animals; D002196:Capillaries / Q000254:growth & development / Q000503:physiopathology; D002199:Capillary Permeability / Q000187:drug effects / Q000502:physiology*; D002784:Cholesterol / Q000097:blood; D003921:Diabetes Mellitus, Experimental / Q000097:blood / Q000503:physiopathology*; D005374:Filtration; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000494:pharmacology*; D008055:Lipids / Q000097:blood; D008297:Male; D009475:Neurons, Afferent / Q000187:drug effects / Q000502:physiology; D011725:Pyridines / Q000494:pharmacology*; D051381:Rats; D017208:Rats, Wistar; D012709:Serum Albumin / Q000378:metabolism*
D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D008055:Lipids; D011725:Pyridines; D012709:Serum Albumin; D002784:Cholesterol; C086276:cerivastatin